MedTrace Logo

Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

NCT01709994 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2012-10-18

No results posted yet for this study

Summary

The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).

Conditions

  • Chronic Kidney Disease Stage 4
  • Chronic Kidney Disease Stage 3

Interventions

DRUG

Aspirin

100 mg/day of aspirin

Sponsors & Collaborators

  • Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales

    lead OTHER

Principal Investigators

  • JOSE LUÑO, MD, PhD · Hospital General Universitario Gregorio Marañon

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01709994 on ClinicalTrials.gov